Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Roflumilast Tablets, 250 mcg (USRLD: Daliresp Tablets, 250 mcg).
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD). It is used to prevent worsening of symptoms in people with severe COPD. The drug will be manufactured at the group’s formulation manufacturing facility in SEZ Ahmedabad, (India).
Roflumilast Tablets, 250 mcg had annual sales of USD 34 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 363 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
India's Real GDP Growth To Exceed 6.5% For 2025-26; Gross Value Added Growth To Surpass 6.3%, Says ICRA
Mannara Chopra Gets Emotional, Sister Mitali Breaks Down At Father's Funeral In Mumbai; Heartbreaking Visuals Surface
Mumbai: Versova Woman Duped Of ₹45 Lakh By Nurse Offering MBBS Seat For Daughter; Accused Arrested
BSE Announces Demat Auction For Settlement DR-653, Offers Invited From Trading Members
